Previous 10 | Next 10 |
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress PR Newswire SAN FRANCISCO , Sept. 7, 2022 /PRNe...
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma PR Newswire SAN FRANCISCO , Aug. 16, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announce...
Nektar Therapeutics Reports Second Quarter 2022 Financial Results PR Newswire SAN FRANCISCO , Aug. 4, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. ...
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financ...
Nektar's bempeg has been shelved and 70% of the workforce let go. Two assets now remain, with uncertain pedigree. It is time to forget this ticker for a long time. After three trial failures and a discontinuation, Nektar Therapeutics ( NKTR ) is finally giving up on ...
3 Methods for Finding Hot Penny Stocks Right Now When it comes to finding penny stocks to buy, there are hundreds of ways to go about it. The most important thing is to have a system in place that you’re comfortable with and that has been proven to work. Because penny stocks ...
We may have seen the bottom already. The S&P 500 is up 6.4% in 2 weeks. The NASDAQ is up 9.2%. The market is trying to tell us something. A long climb down the mountain Here is a year-to-date chart of the S&P 500 index. Was the June 16 th low of 3...
Nektar Therapeutics ( NASDAQ: NKTR ) promoted Jillian B. Thomsen to SVP & CFO; he has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008. Gil Labrucherie, current COO & CFO, has stepped down to pursue another opportu...
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer PR Newswire SAN FRANCISCO , July 1, 2022 /P...
Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 PR Newswire – NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic ...
Nektar Management to Present at Upcoming Investor Conferences PR Newswire SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare C...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...